Filed pursuant to Rule 424(b)(7)
SEC File No. 333-139827
PROSPECTUS SUPPLEMENT NO. 9
(To Prospectus dated January 5, 2007)
127,024 Shares
BioMed Realty Trust, Inc.
Common Stock
Issuable upon Exchange of BioMed Realty, L.P. 4.50% Exchangeable Senior Notes due 2026
This prospectus supplement no. 9 supplements and amends the prospectus dated January 5, 2007,
relating to the resale from time to time by certain selling stockholders of shares of our common
stock that may be issued upon the exchange or redemption of BioMed Realty, L.P.s 4.50%
Exchangeable Senior Notes due 2026.
You should read this prospectus supplement no. 9 in conjunction with the prospectus. This
prospectus supplement no. 9 is not complete without, and may not be delivered or used except in
conjunction with, the prospectus, including any amendments or supplements to it. This prospectus
supplement no. 9 is qualified by reference to the prospectus, except to the extent that the
information provided by this prospectus supplement no. 9 supersedes information contained in the
prospectus.
Selling stockholders, including their transferees, pledgees or donees or their successors, may
from time to time offer and sell pursuant to the prospectus and any accompanying prospectus
supplement any or all of the shares of our common stock which we may issue upon the exchange or
redemption of the notes.
The following table sets forth information, as of June 10, 2009, with respect to the selling
stockholders and the number of shares of our common stock that would become beneficially owned by
each stockholder should we issue our common stock to such selling stockholder that may be offered
pursuant to this prospectus upon the exchange or redemption of the notes. The information is based
on information provided by or on behalf of the selling stockholders. The selling stockholders may
offer all, some or none of the shares of our common stock which we may issue upon the exchange or
redemption of the notes. Because the selling stockholders may offer all or some portion of such
shares of our common stock, we cannot estimate the number of shares of our common stock that will
be held by the selling stockholders upon termination of any of these sales. In addition, the
selling stockholders identified below may have sold, transferred or otherwise disposed of all or a
portion of their notes or shares of our common stock since the date on which they provided the
information regarding their notes in transactions exempt from the registration requirements of the
Securities Act of 1933, as amended.
The number of shares of our common stock issuable upon the exchange or redemption of the notes
shown in the table below assumes exchange of the full amount of notes held by each selling
stockholder at the maximum exchange rate of 31.7561 shares of our common stock per $1,000 principal
amount of notes and a cash payment in lieu of any fractional share. This exchange rate is subject
to adjustment in certain events. Accordingly, the number of shares of our common stock issued upon
the exchange or redemption of the notes may increase or decrease from time to time. The number of
shares of our common stock owned by the other selling stockholders or any future transferee from
any such holder assumes that they do not beneficially own any shares of common stock other than the
common stock that we may issue to them upon the exchange or redemption of the notes.
Based upon information provided by the selling stockholders, none of the selling stockholders
identified below nor any of their affiliates, officers, directors or principal equity holders has
held any positions or office or has had any material relationship with us within the past three
years.
To the extent any of the selling stockholders identified below are broker-dealers, they may be
deemed to be, under interpretations of the staff of the Securities and Exchange Commission,
underwriters within the meaning of the Securities Act of 1933, as amended.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares |
|
|
Percentage of |
|
|
|
|
|
|
Number of |
|
|
Percentage of |
|
|
|
Beneficially |
|
|
Shares |
|
|
|
|
|
|
Shares |
|
|
Shares |
|
|
|
Owned |
|
|
Beneficially |
|
|
Number of |
|
|
Beneficially |
|
|
Beneficially |
|
|
|
Prior to the |
|
|
Owned Prior to |
|
|
Shares Offered |
|
|
Owned After |
|
|
Owned After the |
|
Name |
|
Offering |
|
|
the Offering(1) |
|
|
Hereby |
|
|
the Offering(2) |
|
|
Offering(1)(2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Linden Capital LP(3) |
|
|
127,024 |
|
|
|
* |
|
|
|
127,024 |
|
|
|
|
|
|
|
* |
|
Total |
|
|
127,024 |
|
|
|
* |
|
|
|
127,024 |
|
|
|
|
|
|
|
* |
|
|
|
|
* |
|
Less than 1%. |
|
(1) |
|
Based on a total of 98,030,606 shares of our common stock outstanding as of June 10, 2009. |
|
(2) |
|
Assumes the selling stockholder sells all of its shares of our common stock offered pursuant to this prospectus. |
|
(3) |
|
Linden GP LLC is the general partner of Linden Capital LP. Siu Min Wong, managing member of Linden GP LLC, has
voting and investment control over the securities held by Linden Capital LP. |
You should consider the risks that we have described in Risk Factors beginning on page 2 of
the prospectus and included in our periodic reports and other information that we file with the
Securities and Exchange Commission before investing in our securities.
Neither the Securities and Exchange Commission nor any state securities commission has
approved or disapproved of these securities or passed upon the accuracy or adequacy of the
prospectus or this prospectus supplement no. 9. Any representation to the contrary is a criminal
offense.
The date of this prospectus supplement no. 9 is June 10, 2009.
2